DailyIQ
Last updatedUpdating…

LLY·Eli Lilly and Company

$1188.66
+31.17 (+2.69%)
After Hours
High
$1,206.63
Open
$1,173.62
Market Cap
1.10T
52W High
$1,292.65
Low
$1,158.35
P. Close
$1,188.66
P/E
41.09
52W Low
$776.00
Fwd P/E
25.15
DailyIQ Est.
$1391.32
Inst. Ownership
0.5%
Short Interest
0.81%
Days to Cover
3.4
Technical Score (1D)
55
BULLISH
News Sentiment
70
BULLISH
On Oct 7, Eli Lilly secured a $115 million judgment against Nektar Therapeutics, clearing a multi‑year legal liability that had previously weighed on its balance sheet. The court ruling removed a potential financial burden and was reported to modestly improve Lilly’s risk profile and investor perception of its legal standing. Also on Oct 7, an analysis of Lilly’s recent approvals of Mounjaro and Zepbound noted that the drugs yielded only 311 % and 91 % returns, respectively, and that the market had already priced in the hype surrounding the approvals, leaving investors with sub‑optimal performance. That same day, an analyst reaffirmed a Strong Buy on Lilly, citing its role as a diversification asset for AI‑heavy portfolios and noting that the company trades at roughly 24 × FY2027 EPS, a premium yet not overly expensive valuation. On Oct 6, the healthcare sector was highlighted as resilient amid high inflation and energy costs, with Eli Lilly positioned as a growth‑oriented option that could serve as a shelter during economic uncertainty. Earlier on Oct 6, Lilly reported that both its top and bottom lines beat expectations, driven by robust drug sales and healthy gross margins, and the company lifted its FY2026 guidance to reflect confidence in continued growth. Finally, on Oct 6, Lilly announced an expanded partnership with Gate Bioscience, securing exclusive worldwide rights to the company’s discovery assets and potentially generating up to $870 million in milestone payments contingent on development milestones.
LOW TARGET
$930 -21.5%
2 analysts
MEAN TARGET
$1329 +12.2%
20 analysts
HIGH TARGET
$1600 +35.1%
17 analysts
PRICE RANGE
$930.00 - $1600.00
SB / B / H / S / SS
11/19/7/1/1
DAILYIQ EST.
$1391.32 (+17.5%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NYQ
Country
United States
Website
Symbol
LLY
Description
Eli Lilly and Company is a global pharmaceutical firm specializing in the discovery, development, and commercialization of human medicines. The company's core business revolves around a diverse portfolio of treatments addressing significant health challenges, including diabetes, oncology, and immunological disorders. Key products include diabetes medications like Mounjaro and Trulicity, as well as oncology drugs such as Verzenio. Eli Lilly also offers therapies for conditions like rheumatoid arthritis, psoriasis, and migraine, demonstrating a broad therapeutic focus. Strategic collaborations with various partners, including Incyte and Boehringer Ingelheim, support the company's research and development efforts, driving innovation in the pharmaceutical landscape.
Bought (1Y)
0 shares
$0
Sold (1Y)
16,438.707 shares
$19.3M
Alvarez Ralph-
Award/Grant10.659 shares2026-09-21
Fyrwald J Erik-
Award/Grant8.513 shares2026-09-21
LUCIANO JUAN R-
Award/Grant13.664 shares2026-09-21
Sulzberger Gabrielle-
Award/Grant4.257 shares2026-09-21
Seymour MelissaEVP, Global Quality
Gift12 shares2026-09-09
79/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
31.7%
Revenue CAGR
7.2%
Current Ratio
1.58x
Debt / Equity
1.60x
Return on Equity
77.8%
Earnings Summary
Eli Lilly and Company is a global pharmaceutical firm focused on discovering, developing, and commercializing human medicines across diabetes, oncology, and immunology, with key products such as Mounjaro, Trulicity, and Verzenio. The company operates within the highly competitive drug manufacturing sector, where innovation and pipeline depth drive growth. In the most recent two quarters, Lilly posted EPS of $7.02 in Q3 2025 and $7.54 in Q4 2025, both beating estimates of $5.89 and $6.74 respectively, while revenue climbed from $17.60 billion to $19.29 billion, surpassing the $18.14 billion estimate in Q4 2025; the prior two quarters saw EPS of $6.31 and $5.32 with revenue of $15.56 billion and $13.53 billion, indicating a clear acceleration in both earnings and top line. Historically, Lilly has maintained a steady YoY revenue growth trajectory, with consistent beats in EPS over the last eight quarters, though some quarters (e.g., Q1 2025) saw a slight miss relative to estimates. The pattern suggests robust profitability even when revenue growth decelerates slightly. Recent news highlights Lilly’s focus on obesity and diabetes therapeutics, with positive phase 3 data for Foundayo and eloralintide-tirzepatide combinations, and a strategic shift away from certain degrader programs; these developments reinforce the company’s pipeline strength and may support future earnings momentum.

EPS

EstBeatMiss
$4.93$6.35$7.77$9.19$10.61Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$9.96 - -
Q2'26$6.07$8.38+38.1%
Q1'26$6.79$8.55+25.9%
Q4'25$6.74$7.54+11.9%
Q3'25$5.89$7.02+19.2%
Q2'25$5.59$6.31+12.9%

Revenue

EstBeatMiss
$14.4B$16.9B$19.3B$21.7B$24.1BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$22.6B - -
Q2'26$20.9B$23.0B+9.8%
Q1'26$17.8B$19.8B+11.1%
Q4'25$18.1B$19.3B+6.4%
Q3'25 - $17.6B -
Q2'25 - $15.6B -

Market Data

LLY Stock Snapshot

NEUTRAL55/100
$1184.16−$4.50 (0.4%)
Market cap
1.10T
P/E ratio
41.1
Day range
$1158.35 – $1206.63
News sentiment
70/100 · Bullish
Analyst target
$1328.83 (+12.2%)
Consensus
Buy · 39 analysts
52-week range+52.6% off low · -8.4% from high
$776.00$1292.65
Price $1184.16 DailyIQ Est. $1391.32

LLY is in a holding pattern - neither trend nor momentum has taken control. Positioning shifts among large allocators, not retail flow, set the tone for a name this size.

Behaviour On Record

What LLY's own history says about today's numbers

Realized volatility (21d)
17.4% 23rd pct
Below its peak
-10.5%
vs 200-day average
+6.6%
Up days (1y)
49%

Eli Lilly and Company is currently running 17.4% annualised volatility over the last 21 sessions. Measured against LLY's own 13 years of daily returns rather than a market-wide average, that is the 23rd percentile — unusually subdued by its own history, against a typical reading of 23.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

LLY is trading -10.5% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.0%, and the deepest was -32.6% in 2025. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +6.6% from its 200-day moving average. Against every other day in its history, that gap ranks at the 42nd percentile — close to the gap it normally carries. Over the past year LLY closed higher on 49% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, LLY finished the month higher 8 of 13 times, with a median return of +1.9% and an average of +0.6%. Its strongest month historically has been June at +5.6% on average, its weakest July at -0.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: LLY has opened more than 2% away from the prior close in 71 of 3,268 sessions (2.2% of the time), with the largest gaps running +11.5% and -5.9%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, LLY moved an average of 3.4% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.0% and a largest of -6.1%.

All figures computed from 3,269 daily closes between 2013-10-07 and 2026-10-06, split-adjusted, recomputed daily. Percentiles are against LLY's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of LLY's sector?

Eli Lilly and Company sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
64

Options Market

What is the options market pricing for LLY?

CallsPuts

For Eli Lilly and Company's nearest expiry (2026-10-09, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.82), with at-the-money implied volatility around 34.4%. The options market is pricing roughly a ±2.5% move by that expiry — a range of about $1157.26–$1215.66.

Put/call ratio (2026-10-09)
0.82
ATM implied volatility
34.4%
Total open interest
16,371
Expected move by 2026-10-09
±2.5% ($1157.26–$1215.66)

Analyst Rating Changes

Are analysts turning bullish or bearish on LLY?

Morgan Stanley most recently reiterated its rating on Eli Lilly and Company to Overweight on Oct 7, 2026 with a price target of $1430 (from $1419). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Morgan Stanley — Overweight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 7, 2026Morgan StanleyMaintainedOverweight$1419 → $1430
Sep 28, 2026JP MorganMaintainedOverweight$1400 → $1500
Sep 22, 2026TD CowenReiteratedBuy$1250
Sep 18, 2026GuggenheimMaintainedBuy$1273 → $1284
Sep 10, 2026HSBCMaintainedReduce$850 → $940
Aug 7, 2026Truist SecuritiesMaintainedBuy$1370 → $1376
Aug 6, 2026Wells FargoMaintainedOverweight$1280 → $1330
Aug 6, 2026Cantor FitzgeraldMaintainedOverweight$1350 → $1410
Jul 15, 2026CitigroupMaintainedBuy$1500 → $1600
Jul 14, 2026BernsteinMaintainedOutperform$1300 → $1385
Jul 13, 2026UBSMaintainedBuy$1250 → $1425
Jul 13, 2026GuggenheimMaintainedBuy$1235 → $1273

LLY Competitive Positioning

Eli Lilly and Company (LLY) is tracked alongside these names in Drug Manufacturers - General on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

70/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Eli Lilly (LLY) reaffirmed its position as a leading weight‑loss company after reporting that its drug Zepbound achieved a mean 20.2% weight loss over 72 weeks, outperforming competitors Wegovy and CagriSema. The company’s success contributed to its status as the first trillion‑dollar healthcare stock in 2025. Analysts noted that LLY’s pipeline, which includes several Phase‑3 obesity assets, will be critical to sustaining growth amid increasing competition. The article highlighted that LLY’s strong pipeline and market leadership could help it continue delivering solid returns over the next five years.
What did this article say?
Eli Lilly announced an expanded drug‑discovery partnership with Gate Bioscience, potentially worth $870 million over multiple years. The agreement grants Lilly global development and commercialization rights for therapies that emerge from the collaboration, targeting difficult‑to‑drug proteins in high‑unmet‑need disease areas. The deal strengthens Lilly’s pipeline in oncology and rare diseases, positioning the company to capture new market opportunities.
What did this article say?
Eli Lilly (LLY) broadened its partnership with Gate Bioscience to target additional proteins, adding one new target and an option for a second. The expanded agreement could trigger payments exceeding $870 million if milestones are achieved, though the payout is conditional. Gate receives an upfront payment and research funding, while Lilly gains worldwide development and commercialization rights for selected programs. The deal expands Lilly’s drug‑discovery portfolio, potentially increasing its pipeline depth, but success depends on progressing candidates through preclinical and clinical stages.
What did this article say?
Nektar Therapeutics secured a $115 million judgment against Eli Lilly, eliminating a multi‑year legal liability that had lingered in the market. The court ruling removed a potential financial burden from Lilly’s balance sheet and reduced uncertainty for investors. The decision is expected to modestly improve Lilly’s risk profile and may lift investor confidence in its legal and regulatory standing.
What did this article say?
The analyst reaffirmed a Strong Buy on Eli Lilly (LLY), citing its role as a diversification asset for AI‑heavy portfolios. LLY trades at roughly 24x FY2027 EPS, indicating a premium yet not overly expensive valuation. The commentary highlighted significant institutional ownership and confidence in LLY’s long‑term growth prospects. No new catalysts or guidance changes were disclosed, keeping the outlook stable. The piece underscored LLY’s potential to outperform the S&P 500 over time.
What did this article say?
The article highlighted that healthcare stocks, including Eli Lilly (LLY), are considered resilient during periods of high inflation and energy price volatility. It noted that consumers are willing to pay for health improvements, supporting the sector’s stability. The piece positioned LLY as a growth-oriented option within the healthcare space, suggesting it could serve as a shelter for investors concerned about broader economic pressures.

Technical Analysis

Real-time indicators across multiple timeframes

55
NEUTRAL
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
1 tracked managers · $3.40B combined position · 0 adding, 0 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Fisher Asset Management, LLC• Hold4,453,0620.48%$3.40B2025-11-12
Q3 2025 flow:4.45M sh bought ($3.40B)0 sh sold ($0)net +4.45M sh (+$3.40B)
Congressional Trading Activity
25 disclosed trades · ~$291.5K est. traded value · 11 buys, 14 sells
MemberChamberStateTypeAmountTradedFiled
Dan NewhouseHouseWA04▼ Sell$1K - $15K2026-07-102026-07-17
Michael RulliHouseOH06▼ Sell$1K - $15K2026-07-012026-08-07
Gilbert CisnerosHouseCA31▲ Buy$50K - $100K2026-06-102026-07-02
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-04-142026-05-08
Elizabeth FletcherHouseTX07▼ Sell$1K - $15K2026-04-082026-05-01
Byron DonaldsHouseFL19▲ Buy$1K - $15K2026-04-022026-05-13
Alan ArmstrongSenateOK▼ Sell$1K - $15K2026-03-272026-07-21
David J. TaylorHouseOH02▲ Buy$1K - $15K2026-02-262026-03-06
Angus KingSenate-▼ Sell$1K - $15K2026-02-132026-03-24
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-02-092026-02-20
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-01-162026-02-02
Michael RulliHouseOH06▲ Buy$1K - $15K2026-01-022026-08-07
Angus KingSenate-▲ Buy$1K - $15K2025-12-292026-01-26
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
David J. TaylorHouseOH02▼ Sell$1K - $15K2025-12-102025-12-19
Michael RulliHouseOH06▼ Sell$1K - $15K2025-12-022026-08-07
John BoozmanSenateAR▼ Sell$1K - $15K2025-11-212026-08-24
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Shelley Moore CapitoSenateWV▲ Buy$1K - $15K2025-10-242025-11-04
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
John BoozmanSenateAR▲ Buy$1K - $15K2025-08-222025-09-12
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-08-142025-09-11
David J. TaylorHouseOH02▲ Buy$15K - $50K2025-08-142025-09-02
John BoozmanSenateAR▲ Buy$1K - $15K2025-08-112025-09-12